Loading...
Epigenomics AG
EPGNF•PNK
Healthcare
Medical - Diagnostics & Research
$1.12
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $134000.00 in Q1 2023 to $68114.00 in Q4 2023. Gross profit remained healthy with margins at 90% in Q4 2023 compared to 72% in Q1 2023. Operating income hit $2.16M last quarter, sustaining a consistent 3177% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.30M. Net income rose to $1.88M, while earnings per share reached $2.20. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan